Infinimmune Raises $12 Million in Seed Funding to Pioneer Novel Approach to Antibody Drug Discovery and Development
SAN FRANCISCO--(BUSINESS WIRE)--Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, today announced that it has closed a $12 million seed round led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier. Infinimmune is...
